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Abstract
The mitochondrial transition pore (MTP) is implicated as a mediator of cell injury and death in many situations. The MTP
opens in response to stimuli including reactive oxygen species and inhibition of the electron transport chain. Sporadic
Parkinson’s disease (PD) is characterized by oxidative stress and specifically involves a defect in complex I of the electron
transport chain. To explore the possible involvement of the MTP in PD models, we tested the effects of the complex I
inhibitor and apoptosis-inducing toxin N-methyl-4-phenylpyridinium (MPP) on cyclosporin A (CsA)-sensitive mitochon-
drial swelling and release of cytochrome c. In the presence of Ca2 and Pi, MPP induced a permeability transition in both
liver and brain mitochondria. MPP also caused release of cytochrome c from liver mitochondria. Rotenone, a classic non-
competitive complex I inhibitor, completely inhibited MPP-induced swelling and release of cytochrome c. The MPP-
induced permeability transition was synergistic with nitric oxide and the adenine nucleotide translocator inhibitor
atractyloside, and additive with phenyl arsine oxide cross-linking of dithiol residues. MPP-induced pore opening and
cytochrome c release were blocked by CsA, the Ca2 uniporter inhibitor ruthenium red, the hydrophobic disulfide reagent N-
ethylmaleimide, butacaine, and the free radical scavenging enzymes catalase and superoxide dismutase. MPP neurotoxicity
may derive from not only its inhibition of complex I and consequent ATP depletion, but also from its ability to open the
MTP and to release mitochondrial factors including Ca2 and cytochrome c known to be involved in apoptosis. ß 1999
Elsevier Science B.V. All rights reserved.
0925-4439 / 99 / $ ^ see front matter ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The mitochondrial inner membrane harbors a
unique cyclosporin A (CsA)-sensitive protein com-
plex, referred to as the mitochondrial transition
pore (MTP) [1^4]. The MTP opens as a non-selec-
tive, high conductance ‘megachannel’ which allows
passage of solutes of molecular weight 91500 Da
between the mitochondrial matrix and the cytoplasm.
This causes the mitochondrion to undergo a perme-
ability transition (PT) and subsequent large ampli-
tude swelling [1^3].
MTP opening is controlled by membrane voltage
[1^4] and enhanced by numerous agents, including:
Ca2 and Pi [2,5^7], oxidizing agents and free radi-
cals [1,2,4^9] including nitric oxide (NOc) [10,11], free
fatty acids and products of the phospholipase A2
(PLA2) pathway [2,4,12], atractyloside, which inhib-
its the adenine nucleotide translocator [2,4], and in-
hibitors of the mitochondrial electron transport
chain (ETC) [6,7,13^15]. Pore opening in various sit-
uations may be blocked by CsA [1^4], which specif-
ically binds mitochondrial cyclophilin and prevents
its interaction with the MTP complex [2,4,16], ruthe-
nium red (RuRed), which blocks the mitochondrial
Ca2 uniporter [2,7,13], ADP and Mg2 [2,16,17], or
by disul¢de reagents [1,2,4,8,9,17].
The mitochondrial ETC is impaired in multiple
neurodegenerative diseases including sporadic Par-
kinson’s disease (PD), which speci¢cally involves
NADH:ubiquinone oxidoreductase or complex I
[18^25]. This biochemical defect is both systemic, as
mitochondria from multiple PD tissues including
platelets [18,20], ¢broblasts [22], muscle [23], and
nigral [24] and non-nigral brain [21,25] exhibit re-
duced complex I activity, and arises from mitochon-
drial DNA [18,19], arguing for its primacy in the
disease.
ETC dysfunction, oxidative stress, mitochondrial
damage, and cell death are implicated both in PD
[18^27,35,36] and in experimental parkinsonism in-
duced by the neurotoxin N-methyl-4-phenylpyridi-
nium (MPP) [27^35]. The MTP has been implicated
in cell death in many circumstances, including those
involving ETC inhibition and oxidative stress
[14,15,34,37^39]. Opening of the MTP is associated
with the release of Ca2 currents which may activate
proteases and other factors leading to cell death [40^
43]. Mitochondria also participate in apoptosis via
the release of cytochrome c [44,45], which may be a
direct consequence of MTP opening [46]. It has re-
cently been con¢rmed that brain mitochondria
undergo a PT in response to many of the classic
MTP stimuli [47]. Hence, investigations into the
functioning of the MTP in PD models might provide
insights into the mechanism of neuronal cell death in
PD patients’ brains.
We investigated the e¡ects of acute complex I in-
hibition by the classic parkinsonian neurotoxin N-
methyl-4-phenpyridinium (MPP) on CsA-sensitive
mitochondrial swelling and cytochrome c release
from mitochondria. We determined that MPP
opens the classic MTP in both liver and brain mito-
chondria and investigated the e¡ects of various
known PT inducers and inhibitors on the mechanism
of action of MPP.
2. Materials and methods
2.1. Isolation of rat liver mitochondria
Mitochondria were prepared by standard di¡eren-
tial centrifugation [48], with minor modi¢cations.
Male Sprague-Dawley rats (250^350 g) were fasted
overnight, sacri¢ced by decapitation, and the livers
immediately excised and homogenized on ice and
placed in ice-cold isolation bu¡er containing 70
mM sucrose, 220 mM mannitol, 5 mM HEPES,
0.20 mM EDTA, pH 7.5. Mitochondria were washed
twice in the same bu¡er without EDTA, and resus-
pended in wash bu¡er.
2.2. Isolation of rat brain mitochondria
Mitochondria were prepared by a modi¢cation of
the method of Lai and Clark [49]. Brie£y, four rats
per experiment were decapitated and the brains re-
moved and homogenized on ice in brain isolation
bu¡er (320 mM sucrose, 2 mM K-EDTA, 10 mM
Tris-base, pH 7.4), then centrifuged for 3 min at
1300Ug at 4‡C. The pellet was resuspended and ho-
mogenized in the same bu¡er, centrifuged for 3 min
at 1300Ug, and the two supernatants combined and
centrifuged at 17 000Ug for 10 min. The pellets were
then resuspended and homogenized in a Te£on-glass
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homogenizer, and layered over a Ficoll step gradient
(10 ml of 7.5% Ficoll over 10 ml 10% Ficoll) for
ultracentrifugation for 40 min at 4‡C in a Beckman
ultracentrifuge. The pellet (cell body mitochondria)
was resuspended in wash bu¡er (same as isolation
but no EDTA) and recentrifuged at 9800Ug two
times. The mitochondria were then resuspended in
wash bu¡er.
2.3. Mitochondrial incubations and MTP assays
Mitochondria were kept on ice until being added
to assay bu¡er at about 1 mg mitochondrial protein/
ml at 25‡C. The liver assay bu¡er contained 70 mM
sucrose, 214 mM mannitol, 5 mM HEPES, and
5 mM glutamate/0.5 mM malate (glu/mal) or 5 mM
succinate, pH 7.5. The brain assay bu¡er was the
same as the brain wash bu¡er, except for the addi-
tion of 5 mM glutamate/0.5 mM malate. Ca2 and Pi
concentrations and other additions are as indicated
in the ¢gure legends. 500 WM or 1.0 mM Pi was
added to induce swelling. In most cases the mito-
chondria were preincubated for 5 min in the assay
bu¡er at 25‡C with or without additions. During
these preincubations, negligible swelling was ob-
served.
Mitochondrial swelling was monitored via the de-
crease in absorbance at 540 nm measured in a Varian
Cary model 4E spectrophotometer. Each experiment
shown is representative of at least three similar ex-
periments performed on separate mitochondrial
preparations.
2.4. Estimation of the e¡ective pore size through
solute size exclusion experiments
To determine whether the MTP opened by MPP
is the same as the MTP opened by the classic PT
inducers Ca2Pi and phenyl arsine oxide (PhAsO),
we measured the e¡ective pore ‘size’ in terms of mo-
lecular weight by means of exclusion of various size
solutes. Polyethylene glycol molecules (PEGs) of var-
ious molecular weights were prepared according to
Pfei¡er et al. [50] in order to give a constant osmotic
pressure of about 300 mosm, and were mixed with
assay bu¡er (also approx. 300 mosm) such that 40%
of the osmotic pressure was derived from the PEG
solutions.
2.5. Oxygen consumption measurements
Oxygen consumption was monitored polarograph-
ically with an oxygen meter (YSI Model 5300, Col-
orado Springs, CO). Mitochondria were incubated
for 5 min at 25‡C in assay bu¡er with 5 mM gluta-
mate/0.5 mM malate or 5 mM succinate plus or mi-
nus various concentrations of MPP or rotenone.
3 mM Pi and 60 nmoles ADP were added to initiate
respiration. The e¡ects of MPP and rotenone on
oxygen consumption and ADP/Pi ratios were deter-
mined by the method of Estabrook [51].
2.6. Mitochondrial uptake of MPP+
In order to determine whether isolated mitochon-
dria assayed under our conditions could signi¢cantly
concentrate MPP and whether opening of the MTP
by Ca2Pi a¡ects the intramitochondrial [MPP],
we measured the relative mitochondrial concentra-
tion of [3H]MPP (NEN, Life Science Products, Bos-
ton, MA). [14C]Inulin (MW 5^5.5 kDa; NEN Life
Science Products), a water-soluble extracellular
marker polysaccharide, was used to measure extra-
mitochondrial trapping of MPP. Mitochondria
were harvested as described above, and incubated
in assay bu¡er plus 1 WCi/ml [3H]MPP, 0.1 WCi/ml
[14C]inulin, and 100 WM (non-labeled) MPP for 0^7
min. Energized mitochondria were incubated in assay
bu¡er with glu/mal for 0^5 min at 25‡C. 100 WM
Ca2/1.0 mM Pi were added for 1^2 min to samples
preincubated for 5 min at 25‡C. Deenergized mito-
chondria were treated as above, except for the omis-
sion of glu/mal and the addition of 125 WM Ca2/
1.250 mM Pi to both the suspension bu¡er and assay
bu¡er.
2.7. Mitochondrial protein measurements
Mitochondrial protein was determined by the
Lowry protein assay method [52] with bovine serum
albumin as standard.
2.8. Cytochrome c measurements
Supernatants were obtained from the mitochon-
drial assays via 1 min centrifugation in a tabletop
Eppendorf. Cytochrome c supernatant concentra-
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tions were determined by the di¡erence spectra meth-
od of Vanneste [53], with modi¢cations. Brie£y, the
concentration of cytochrome c is calculated from
vA551ÿ538 of the di¡erence spectrum of dithionate-
reduced cytochrome c minus oxidized cytochrome
c, using an extinction coe⁄cient of 21.1 mM31
cm31. The identi¢cation of cytochrome c was veri¢ed
by HPLC analysis. A Kromasil C8 column (5 Wm,
Alltech) was perfused at 1 ml/min with 30% acetoni-
trile/70% water containing 0.1% tri£uoroacetic acid.
Two minutes after injection a linear gradient to 80%
acetonitrile/20% water/0.1% TFA over 10 min eluted
cytochrome c at 8.5^9 min, using horse heart cyto-
chrome c as an external standard and detection at
280 nm.
2.9. Materials
MPP was obtained from RBI (Natick, MA), and
prepared in water. All other reagents were from Sig-
ma (St. Louis, MO), unless otherwise noted. Super-
oxide dismutase (SOD) was prepared in 50 mM
glycine-NaOH, pH 9.5. Catalase (CAT) was pre-
pared in 50 mM KPi, pH 7.0. Rotenone was pre-
pared in methanol. CsA, butacaine, N-ethylmalei-
mide (NEM), and PhAsO were prepared in
ethanol. The solvents were present in the assay bu¡er
at ¢nal concentrations 9 0.5%, at which they had no
e¡ects on swelling.
3. Results
3.1. MPP+ inhibits complex I and causes a
permeability transition in Ca2+ and Pi-treated
isolated mitochondria
Liver mitochondria underwent a PT due to MPP
in the presence of Ca2 and Pi. Mitochondria were
preincubated with MPP for 5 min at 25‡C in glu-
tamate and malate assay bu¡er, then loaded with 50
WM Ca2 for 2 min. Addition of 500 WM Pi 2 min
later induced a PT (Fig. 1). Identically treated mito-
chondria preincubated without MPP (Ca2/Pi con-
Fig. 1. Isolated rat liver mitochondria undergo a PT in the presence of Ca2Pi and MPP. Mitochondria were preincubated for 5 min
at 25‡C in liver assay bu¡er with 5 mM glutamate/0.5 mM malate plus or minus the indicated concentrations of MPP. 50 WM Ca2
was added at t0 (the start of recording), and 500 WM Pi was added at 2 min. Where indicated, 2.5 WM CsA was included in the prein-
cubation.
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trol) did not undergo a PT. Mitochondria energized
by the complex II substrate succinate show a similar
but more robust response to MPP (data not
shown). The concentration dependence of MPP-in-
duced pore opening was triphasic: concentrations
lower than approx. 50 WM did not induce a PT, while
100^600 WM MPP showed increasing stimulation,
which fell o¡ at higher concentrations, such that con-
centrations greater than 1.2 mM were ine¡ective in
inducing a PT (Fig. 1).
Similar results were found in rat brain mitochon-
dria (Fig. 2), although CsA was relatively ine¡ective
as compared to liver mitochondria, consistent with
the results of others [47]. The combination of CsA
and 500 WM Mg2, which is also a PT inhibitor
[2,16,17], was highly e¡ective in blocking the e¡ects
of MPP in brain mitochondria.
Micromolar concentrations of the classic non-
competitive complex I inhibitor, rotenone [54], in-
hibited the PT. Mitochondria preincubated for
5 min at 25‡C and treated with 100 WM Ca2 and
1 mM Pi underwent rapid swelling (Fig. 3). Mito-
chondria preincubated with 1^10 WM rotenone did
not exhibit a PT under the same conditions. Pre-
incubation with 500 WM MPP led a PT upon ad-
dition of 50 WM Ca2/500 WM Pi. Strikingly, in-
clusion of 1 WM rotenone in the preincubate with
MPP completely blocked the MPP-induced PT
(Fig. 3).
In order to verify that the contrasting e¡ects on
PT induction by rotenone and MPP were not due
to di¡erences in inhibition of respiration, we meas-
ured complex I-dependent respiration in the presence
of either rotenone or MPP. Preincubation of mito-
chondria in the glu/mal MTP assay bu¡er plus 3 mM
Pi with MPP for 5 min signi¢cantly inhibited ADP-
induced respiration at concentrations between 50 and
600 WM, and essentially blocked respiration at higher
doses (data not shown), and did not inhibit succi-
nate-based respiration, consistent with the estab-
lished e¡ects of MPP on complex I [55^58]. Rote-
none completely inhibited glu/mal, but not succinate,
-driven respiration at concentrations v 1 WM, again
as expected.
Fig. 2. Induction of a PT in brain mitochondria by MPP in the presence of Ca2Pi. Mitochondria were added to brain assay bu¡er
at 25‡C and in the presence of the indicated concentrations of MPP. Addition of 25 WM Ca2 was made at t0, and 500 WM Pi at
2 min. Where indicated, CsA þ Mg2 (500 WM) were included in the preincubation with 600 WM MPP.
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3.2. The MPP+-induced PT is synergistic with the
adenine nucleotide translocator inhibitor
atractyloside
The adenine nucleotide translocator is thought to
be one of the components of the MTP, and its open
conformation is favored by oxidized nucleotides and
atractyloside [2,4,16]. We found that atractyloside
was synergistic with low concentrations of MPP
in causing a PT (Fig. 4). The addition of 50 WM
atractyloside (after 25 WM Ca2/500 WM Pi) to mito-
chondria preincubated with 50 or 100 WM MPP
(concentrations which caused little swelling on their
own, Fig. 1) caused a substantial leftward shift of the
MPP-induced swelling curve (Fig. 4).
3.3. The MPP+-induced PT is additive with dithiol
crosslinking and blocked by N-ethylmaleimide
PhAsO increases the open probability of the MTP
by oxidizing a vicinal dithiol site on the pore [2,4].
We found that low concentrations of PhAsO were
additive with MPP in inducing a PT (Fig. 5) in
the presence of 25 WM Ca2 and 500 WM Pi. As
this might indicate a common site of attack by
MPP and PhAsO, we tested whether GSH or the
hydrophilic dithiol reductant dithiothreitol would
inhibit the MPP-induced PT. Fig. 5 shows that
neither of these reagents prevented the PT induced
by MPP (at concentrations up to 5 mM). However,
the hydrophobic dithiol reagent NEM, which is
known to prevent the arsine oxide or PhAsO-induced
PT [2,4,9,17], did prevent the e¡ects of MPP at
low doses (1^20 WM). NEM also prevented the
PT induced by PhAsO and PhAsO plus MPP
(Fig. 5).
3.4. The MPP+-induced PT is synergistic with nitric
oxide donors
As nitrous compounds such as NOc and NOO3
are known PT inducers [10,11], and NOc is involved
Fig. 3. Inhibition of Ca2Pi- and MPP-induced PT by rotenone. Liver mitochondria were preincubated plus or minus 1 WM rotenone
and/or 500 WM MPP for 5 min at 25‡C in glu/mal. 50 WM Ca2/500 WM Pi (low Ca2Pi) or 100 WM Ca2/1.0 mM Pi (high Ca2Pi)
were added at t0.
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Fig. 5. MPP-induced swelling is potentiated by PhAsO and inhibited by NEM, but not by GSH or dithiothreitol (DTT). Mitochon-
dria were preincubated for 5 min either alone or with 300 WM MPP plus or minus 20 WM NEM, 5 mM DTT, or 5 mM GSH.
Where indicated, 20 WM PhAsO was added at t0. 25 WM Ca2 was added at t0 and 500 WM Pi at 2 min.
Fig. 4. Atractyloside (ATR) induces mitochondrial swelling and potentiates the MPP-induced PT. Mitochondria were preincubated
for 5 min in the presence or absence of the indicated MPP concentrations. At t0, Ca2Pi (25 WM/500 WM) or Ca2Pi plus atractylo-
side (50 WM) were added.
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Fig. 6. MPP-induced swelling is potentiated by nitric oxide donors. Mitochondria were preincubated for 5 min alone or with 100^
300 WM MPP. 50 WM Ca2 was added at t0 and 500 WM Pi at 2 min. Where indicated, 50 WM SNAP was added at 5 min. CsA,
where indicated, was present in the preincubate at 2.5 WM.
Fig. 7. Inhibition of the MPP-induced PT by the PLA2 inhibitor butacaine and the Ca2 uniporter inhibitor RuRed. Mitochondria
were preincubated for 5 min at 25‡C alone or with 600 WM MPP þ butacaine, as indicated. 50 WM Ca2 was added at t0 and 500
WM Pi at 2 min. RuRed (1 WM) was added at 2 min (after Ca2 loading) where indicated.
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in in vivo MPP neurotoxicity [58^60], we explored
whether NOc donors could potentiate MPP’s e¡ects
on the transition pore. S-Nitroso-N-acetylpenicill-
amine (SNAP) was able to induce a delayed PT in
the presence of 25 WM Ca2 and 500 WM Pi (Fig. 6).
50 WM SNAP also strongly potentiated the MPP-
induced PT. To ensure that this e¡ect was not pecu-
liar to SNAP, we also tested the e⁄cacy of the NOc
donor sodium nitroprusside. Sodium nitroprusside
(200 WM) was also capable of causing a PT in the
presence of Ca2 and Pi, and also potentiated the
e¡ects of MPP (data not shown).
3.5. The MPP+-induced PT is inhibited by butacaine
As there are indications that free fatty acids and
products of the PLA2 pathway may contribute to
MTP opening [2,4,9,12], we tested whether the
PLA2 inhibitor butacaine [14,61] could prevent the
e¡ects of MPP on the MTP. Butacaine, at 50 WM
and higher concentrations, signi¢cantly inhibited the
MPP-induced PT (Fig. 7). In addition, butacaine
inhibited the PT induced by high doses of Ca2Pi
(data not shown).
3.6. The MPP+-induced PT is inhibited by
ruthenium red
As Ca2 cycling through the mitochondrial Ca2
uniporter is thought to contribute to MTP opening
[2,3], we tested the e¡ects of the Ca2 uniporter in-
hibitor ruthenium red (RuRed) [2,4] on the MPP-
induced PT. Mitochondria were preincubated for
5 min with MPP and loaded with 50 WM Ca2 at
t0. 1 WM RuRed was then added (along with 500 WM
Pi) at t = 2 min. As shown in Fig. 7, RuRed com-
pletely blocked the PT caused by MPP.
3.7. The MPP+-induced PT is inhibited by superoxide
and hydrogen peroxide scavengers
As MPP is known to produce reactive oxygen
species (ROS) both in vitro [29^32,62^64] and in
vivo [27,65], we tested the e¡ects of SOD and CAT
on the MPP-induced PT. Increasing doses of SOD
(up to 500 U) produced increasing inhibition of the
PT (Fig. 8). However, inhibition was incomplete, and
even the highest doses of SOD only delayed the onset
of PT. Similarly, CAT, which scavenges H2O2, was
Fig. 8. Inhibition of MPP-induced PT by SOD and CAT. Liver mitochondria were preincubated for 5 min at 25‡C with 600 WM
MPP þ SOD and/or CAT at the indicated doses. 50 WM Ca2 was added at t0 and 500 WM Pi at 2 min.
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also found to provide dose-dependent protection.
400 U CAT provided signi¢cant protection from
both the MPP and Ca2Pi-induced PTs. The com-
bination of 500 U SOD and 400 U CAT provided
additive protection, indicating the involvement of
both superoxide radicals and hydrogen peroxide in
this process.
3.8. Determination of the e¡ective ‘size’ of pore
opened by Ca2+Pi, PhAsO, and MPP
+
In order to determine whether the MTP opened by
MPP is the same pore as that activated by the clas-
sic PT inducers, Ca2Pi and PhAsO, we determined
the e¡ective pore ‘size’ induced by each of these via
exclusion of PEG molecules. Using the method of
Pfei¡er et al. [50], PEG solutions of 400^1450 kDa
were prepared with a constant osmotic pressure of
300 mosm. These were mixed with assay bu¡er in the
ratio of 4:6 (PEG solution:assay bu¡er). Increasing
molecular weight PEGs inhibited swelling in re-
sponse to Ca2/Pi (100 WM/1 mM), PhAsO (40
WM), and MPP (500 WM). The curves were very
similar for each treatment, consistent with the open-
ing of the same pore in each case. A given PEG MW
inhibited the MPP-induced PT slightly less (signi¢-
cantly di¡erent from Ca2Pi for 400 and 600 MWs,
P6 0.05) than it inhibited the Ca2Pi- or PhAsO-
induced PTs.
3.9. Determination of the acute uptake of MPP+ by
isolated mitochondria
[3H]MPP uptake experiments showed that MPP
is rapidly (in 6 30 s) concentrated into both ener-
gized and deenergized mitochondria under our con-
ditions, and that this concentration does not signi¢-
cantly increase over the 7 min incubations tested
(Fig. 10). Mitochondria deenergized by deprivation
of substrates and incubation with high Ca2Pi con-
centrations still had signi¢cant uptake of MPP, in-
dicating a di¡usional component. Addition of 100
WM Ca2/1.0 mM Pi (to completely open the MTP)
to energized mitochondria at t = 5 min did not sig-
ni¢cantly a¡ect (by one-way analysis of variance or
ANOVA) the mitochondrial concentration of MPP
Fig. 10. Mitochondrial uptake of MPP in both energized and
deenergized assay conditions over a 7 min incubation period.
Mitochondria were treated exactly as in the PT assays, except
for the addition of [3H]MPP and [14C]inulin, as described in
Section 2, to speci¢cally measure mitochondrial-trapped MPP.
The energized mitochondria were incubated in the presence of
5 mM glutamate/0.5 mM malate. 100 WM Ca2/1.0 mM Pi was
added after 5 min to the energized mitochondria to induce the
PT. The deenergized mitochondria were incubated without sub-
strates and in the presence of 125 WM Ca2/1.25 mM Pi to in-
duce complete permeabilization.
Fig. 9. Inhibition by PEG molecules of MTP opening by high
Ca2Pi, MPP, and PhAsO. Liver mitochondria were preincu-
bated for 5 min at 25‡C plus or minus 600 WM MPP in assay
bu¡er mixed with PEG solution in a 6:4 ratio. 50 WM Ca2/
500 WM Pi was added at t0 to the MPP-treated mitochondria.
For the PhAsO experiment, 25 WM Ca2/500WM Pi was added
along with 20 WM PhAsO at t0. For the Ca2Pi experiment,
100 WM Ca2/1.0 mM Pi was added at t0.
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within a timeframe allowing complete PT (Fig. 10).
The energized mitochondria had a signi¢cantly great-
er uptake compared to the deenergized mitochondria
at all timepoints except t = 0 and 5 min (unpaired
t-tests).
3.10. Release of cytochrome c by isolated
mitochondria treated with Ca2+Pi, PhAsO, and
MPP+ with or without inhibitors
Mitochondria treated as in the PT assays released
cytochrome c into the supernatants after treatment
with various inducers (Fig. 11). The detection of cy-
tochrome c was veri¢ed by both di¡erence spectra
and HPLC analysis. The cytochrome c peak seen
on HPLC at 280 nm 8.5^9.0 min after injection cor-
responded to the peak seen at 551 nm (data not
shown). Mitochondria treated with high concentra-
tions of Ca2Pi, PhAsO, or MPP released signi¢-
cant amounts of cytochrome c compared to Ca2Pi
controls (P6 0.05, unpaired t-tests). The release of
cytochrome c by MPP was signi¢cantly blocked by
preincubation with 2 WM NEM, 50 WM butacaine,
600 U CAT, or 2 WM CsA (Fig. 11). Micromolar
concentrations of rotenone and RuRed also e⁄-
ciently inhibited high Ca2Pi- and MPP-induced
release of cytochrome c (data not shown). All of
these treatments except CAT normalized the levels
of cytochrome c released by MPP to control levels.
Hence, cytochrome c release can be a direct conse-
quence of MTP opening by agents including MPP.
4. Discussion
The neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP) causes a parkinsonian syn-
drome in humans and primates after selective uptake
of its metabolite MPP into dopaminergic neurons
[26,27,62]. MPP is concentrated into mitochondria
down the electrochemical gradient, and selectively
and potently inhibits complex I of the electron trans-
port chain [28,29,62]. This inhibition is thought to
kill cells via impaired ATP production [30^
33,63,66], loss of the mitochondrial membrane poten-
tial [10,63], and the formation of ROS [30^33,63^65]
in a nitric oxide synthase (NOS)-dependent manner
[58^60]. In light of our present ¢ndings that MPP
also induces the mitochondrial PT and releases cyto-
chrome c via a complex I-dependent, free radical-
mediated process, we hypothesize that these stressors
may lead to cell death in a process dependent on the
MTP. This is consistent with the literature showing
that both ETC inhibition [7,10^12] and ROS [2,4^
8,10,11] stimulate MTP opening.
MPP and rotenone are thought to inhibit com-
plex I at the same or a very nearby site [30,31,67],
and both are known free radical generators
[10,11,27^33]. Rotenone, at concentrations which
completely block complex I, prevented the MPP-
induced PT. This may re£ect competition at the
same binding site(s), indicating that MPP probably
requires complex I inhibition to open the MTP.
Others have used rotenone under di¡erent condi-
tions to induce MTP opening [10,13]. Rotenone may
induce a PT in the presence of Ca2 and succinate in
a process dependent on H2O2 production [13] and
synergistic with NOc [10]. However, under conditions
Fig. 11. Release of cytochrome c into the supernatants of mito-
chondria treated with various PT inducers. Mitochondria were
preincubated with no additions or with 90 or 600 WM
MPP þ 2 WM NEM, 50 WM butacaine (But), 600 U CAT, or
2 WM CsA. For the PhAsO experiment, 20 WM PhAsO was
added at t0. 50 WM Ca2 and 500 WM Pi were added at 0 and
2 min, respectively, in all cases, except for the high Ca2Pi con-
dition, in which 100 WM Ca2/1 mM Pi were added at t0. Cyto-
chrome c was measured by di¡erence spectral analysis and con-
¢rmed by HPLC analysis, as described in Section 2.
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of PT induction by Ca2Pi and arsine oxide plus
Ca2Pi, high concentrations of rotenone were shown
to inhibit the PT [8]. This may be due to its preven-
tion of the oxidation of NADH and NADPH [8],
consistent with the protective e¡ects shown by other
metabolic inhibitors [68^70] and ETC substrates [71^
73]. Therefore, under our conditions of Ca2Pi-in-
duced PT, high concentrations of rotenone (which
completely block complex I) are probably inhibiting
the PT by keeping the NAD pool in a reduced state.
Similarly, complete blockade of complex I and inhi-
bition of pyridine oxidation at high MPP concen-
trations may explain MPP’s ‘inverted-U’ concentra-
tion-response curve. We have subsequently found
that low concentrations of rotenone ^ which only
partially block complex I ^ also induce a PT (Parks
et al., in preparation). A similar concentration-re-
sponse curve was also seen with the compound butyl-
ated hydroxytoluene [73].
MPP seems to open the MTP via an oxidative
mechanism. Its PT was inhibited by the superoxide
scavenger SOD and the hydrogen-peroxide scavenger
CAT (Fig. 8), and, previously, by the dopamine re-
ceptor agonist and apparent hydroxyl-radical scav-
enger pramipexole [74]. In vivo, nigrostriatal MPP
neurotoxicity is dependent on NOS [59^61], which
forms nitric oxide NOc, a potential precursor to the
toxic peroxynitrite (ONOO3) and cOH species [61].
These oxidative stresses likely contribute to the death
of vulnerable neurons in MPTP parkinsonism.
It is plausible that these ROS might stimulate
aberrant MTP opening in PD, as the MTP is highly
redox sensitive [2,4,8], and, as we and others have
shown [2,4^11], its opening probability is increased
by various oxidants including NOc. Packer et al. [10]
showed that MPP seemed to depend on NOc for
Ca2-dependent Ca2 release and mitochondrial de-
polarization in isolated rat liver mitochondria, which
they speculated acts through the peroxynitrite anion.
However, they did not study the e¡ects of MPP and
NOc on CsA-sensitive large-amplitude swelling, nor
did they ¢nd e¡ects of MPP on the MTP in the
absence of NOc [10], in contrast to the present study.
MPP may also have other signi¢cant modes of
action. The MPP-induced PT was clearly dependent
on Ca2, and the Ca2 uniporter inhibitor RuRed
completely abrogated MPP’s e¡ects when added
after Ca2 (Fig. 7). This shows that not simply
Ca2 loading, but Ca2 cycling, was required for
the PT to occur, as found under other conditions
[2,3,10,13]. We also observed a protective e¡ect of
butacaine (Fig. 7), indicating a possible role of
PLA2 activity in MPP’s pore opening. This is con-
sistent with other work showing a protective e¡ect of
other PLA2 inhibitors on MPP-induced cell death
[75]. However, PLA2 inhibitors including butacaine
are known to have other e¡ects [12,61], which may
contribute to their inhibition of MTP opening.
Whatever its mechanism of action turns out to be,
MPP clearly acts to increase the open probability of
the MTP. Hence, the observed synergistic e¡ect with
other PT inducers, including the adenine nucleotide
translocator inhibitor and PT inducer atractyloside
(Fig. 4) and NOc (Fig. 6). MPP was also additive
with the disul¢de oxidant, PhAsO (Fig. 5). It is
tempting to speculate that MPP acts at least parti-
ally through oxidation of a critical PhAsO-sensitive
dithiol site because of this additive e¡ect with PhAsO
and its protection by NEM (Fig. 5), which blocks
PhAsO-sensitive sites [2,4,17]. However, NEM is
known to have other e¡ects on mitochondria, includ-
ing inhibition of Pi transport [76], and the hydro-
philic disul¢de reductants GSH and dithiothreitol
and the hydrophobic disul¢de reagent, monobromo-
bimane [76] failed to prevent the MPP-induced PT
(Fig. 5). Yet, Bernardi has proposed [4,8] that there
is a disul¢de (‘P’) site that is sensitive to pyridine
nucleotide oxidation, and which is protected by
NEM but not by dithiothreitol or monobromobi-
mane. Hence, this may indicate that MPP oxidizes
a hydrophobic disul¢de site on the MTP.
It seems clear that MPP opens the classic mito-
chondrial pore. We found its e¡ect to be completely
blocked by the prototypical MTP inhibitor, CsA.
Also, the PEG experiments clearly show the similar-
ity in e¡ective MW ‘size’ pores induced by Ca2Pi,
PhAsO, and MPP (Fig. 9). MPP, however, may
stimulate the opening of the MTP to a larger diam-
eter, as other e¡ectors are known to do [50].
Opening of the MTP may provide a mechanism by
which complex I inhibition and ROS production lead
to cell death. It has previously been shown that
MPP causes CsA-inhibitable cell death in cultured
hepatocytes [34]. We hypothesize that cytochrome c
release following MTP opening is the signal that in-
duces the cell death program. Cytochrome c is
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known to induce apoptosis via activation of caspases
[44,45,77]. We found that MPP directly releases cy-
tochrome c from isolated liver mitochondria (Fig.
11). This release was speci¢cally blocked to varying
degrees by all of the agents which inhibited the
MPP-induced PT, indicating that cytochrome c re-
lease is associated with MTP opening. These results
are consistent with those of Du et al. [77], who found
that MPP releases cytochrome c in cultured cerebel-
lar neurons, con¢rming that our results in liver mi-
tochondria should apply to the brain. Hence,
MPP’s mechanism action in inducing cell death
may well be more complicated than simple inhibition
of complex I and ATP depletion.
In conclusion, we have shown that MPP opens
the classic mitochondrial transition pore via an oxi-
dative mechanism. However, the possible role of the
MTP in the pathogenesis of Parkinson’s disease re-
mains speculative. Nevertheless, there is a wealth of
evidence for altered Ca2 handling and oxidative
stress both in PD models, including cells depleted
of their mitochondrial DNA and repopulated with
mitochondrial DNA from PD patients (hence, ‘PD
cybrids’) [18,26,27], and in the PD brain (for reviews,
see [35,36]). We hypothesize that these mitochondrial
metabolic and oxidative stresses may lead to aber-
rant opening of the MTP in PD cells. This would
cause further mitochondrial damage and the release
of pro-apoptotic mitochondrial signals such as cyto-
chrome c, which translocate to the nucleus to induce
the cell death program.
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